JPH09509926A - アンジオテンシンのat1及びat2レセプターが関係する疾病の治療のためのイミダゾール誘導体の使用、いくつかのこれらの化合物、それらの製造、それらの薬剤としての用途並びにそれらを含有する製薬組成物 - Google Patents
アンジオテンシンのat1及びat2レセプターが関係する疾病の治療のためのイミダゾール誘導体の使用、いくつかのこれらの化合物、それらの製造、それらの薬剤としての用途並びにそれらを含有する製薬組成物Info
- Publication number
- JPH09509926A JPH09509926A JP7522727A JP52272795A JPH09509926A JP H09509926 A JPH09509926 A JP H09509926A JP 7522727 A JP7522727 A JP 7522727A JP 52272795 A JP52272795 A JP 52272795A JP H09509926 A JPH09509926 A JP H09509926A
- Authority
- JP
- Japan
- Prior art keywords
- groups
- amino
- formula
- group
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 title claims description 342
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000003814 drug Substances 0.000 title claims description 10
- 101150116411 AGTR2 gene Proteins 0.000 title description 3
- 102000015427 Angiotensins Human genes 0.000 title description 3
- 108010064733 Angiotensins Proteins 0.000 title description 3
- 150000002460 imidazoles Chemical class 0.000 title description 3
- 101150059573 AGTR1 gene Proteins 0.000 title description 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 64
- 125000005843 halogen group Chemical group 0.000 claims abstract description 45
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 38
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 28
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 25
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 22
- 125000002252 acyl group Chemical group 0.000 claims abstract description 21
- 102000005862 Angiotensin II Human genes 0.000 claims abstract description 20
- 101800000733 Angiotensin-2 Proteins 0.000 claims abstract description 20
- 229950006323 angiotensin ii Drugs 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 230000000638 stimulation Effects 0.000 claims abstract description 6
- -1 amino radicals Chemical class 0.000 claims description 277
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 135
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 102
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 87
- 125000003118 aryl group Chemical group 0.000 claims description 71
- 238000006243 chemical reaction Methods 0.000 claims description 68
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 68
- 125000004432 carbon atom Chemical group C* 0.000 claims description 56
- 125000000524 functional group Chemical group 0.000 claims description 52
- 239000002253 acid Substances 0.000 claims description 48
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 27
- 150000001408 amides Chemical group 0.000 claims description 26
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 125000006239 protecting group Chemical group 0.000 claims description 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 125000004429 atom Chemical group 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 15
- 150000002148 esters Chemical group 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 150000007524 organic acids Chemical class 0.000 claims description 10
- 235000005985 organic acids Nutrition 0.000 claims description 10
- 125000004434 sulfur atom Chemical group 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 150000007522 mineralic acids Chemical class 0.000 claims description 9
- 150000007530 organic bases Chemical class 0.000 claims description 9
- 125000003158 alcohol group Chemical group 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
- 150000007529 inorganic bases Chemical class 0.000 claims description 7
- 238000007127 saponification reaction Methods 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000005555 sulfoximide group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 150000002825 nitriles Chemical class 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- 239000005973 Carvone Substances 0.000 claims description 4
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 238000005658 halogenation reaction Methods 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 208000037804 stenosis Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 208000037849 arterial hypertension Diseases 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 238000005886 esterification reaction Methods 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 150000002576 ketones Chemical group 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 3
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- NDDSFWSLVKEYBE-UHFFFAOYSA-N 5-(difluoromethylsulfanyl)-2-propyl-3-[[4-[2-(thiophen-2-ylmethylcarbamoylsulfamoyl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid Chemical compound CCCC1=NC(SC(F)F)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC=2SC=CC=2)C=C1 NDDSFWSLVKEYBE-UHFFFAOYSA-N 0.000 claims description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 2
- STHCGNQDQSSRDJ-UHFFFAOYSA-M [Na+].C1(CCCCC1)CNC(=O)NS(=O)(=O)C1=C(C=CC=C1)C1=CC=C(C=C1)CN1C(=NC(=C1C(=O)[O-])SC)CCC Chemical compound [Na+].C1(CCCCC1)CNC(=O)NS(=O)(=O)C1=C(C=CC=C1)C1=CC=C(C=C1)CN1C(=NC(=C1C(=O)[O-])SC)CCC STHCGNQDQSSRDJ-UHFFFAOYSA-M 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 125000002720 diazolyl group Chemical group 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 125000002560 nitrile group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001391 thioamide group Chemical group 0.000 claims description 2
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 claims 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- PWKBTHNPYPRDRT-UHFFFAOYSA-N 2-[3-[[4-[2-(benzylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-5-methylsulfanyl-2-propylimidazol-4-yl]-2-hydroxy-2-phenylacetic acid Chemical compound CCCC1=NC(SC)=C(C(O)(C(O)=O)C=2C=CC=CC=2)N1CC(C=C1)=CC=C1C1=CC=CC=C1S(=O)(=O)NC(=O)NCC1=CC=CC=C1 PWKBTHNPYPRDRT-UHFFFAOYSA-N 0.000 claims 1
- SHEKLYPDAUFKBO-UHFFFAOYSA-N 2-[3-[[4-[2-(benzylsulfamoyl)phenyl]phenyl]methyl]-5-methylsulfanyl-2-propylimidazol-4-yl]-2-hydroxyacetic acid Chemical compound CCCC1=NC(SC)=C(C(O)C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NCC=2C=CC=CC=2)C=C1 SHEKLYPDAUFKBO-UHFFFAOYSA-N 0.000 claims 1
- USRXDGXGQNWTHA-UHFFFAOYSA-N 2-butyl-5-methylsulfanyl-3-[[4-[2-(thiophen-2-ylmethoxycarbonylsulfamoyl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid Chemical compound CCCCC1=NC(SC)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)OCC=2SC=CC=2)C=C1 USRXDGXGQNWTHA-UHFFFAOYSA-N 0.000 claims 1
- OEXKAYUIQXKCCO-UHFFFAOYSA-N 2-butyl-5-methylsulfanyl-3-[[4-[2-(thiophen-3-ylmethoxycarbonylsulfamoyl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid Chemical compound CCCCC1=NC(SC)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)OCC2=CSC=C2)C=C1 OEXKAYUIQXKCCO-UHFFFAOYSA-N 0.000 claims 1
- RDTNMFSCJCEORO-UHFFFAOYSA-N 3-[[4-[2-(benzylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-5-(difluoromethylsulfanyl)-2-propylimidazole-4-carboxylic acid Chemical compound CCCC1=NC(SC(F)F)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC=2C=CC=CC=2)C=C1 RDTNMFSCJCEORO-UHFFFAOYSA-N 0.000 claims 1
- BFZNLNWLXDQTOV-UHFFFAOYSA-N 3-[[4-[2-(benzylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-5-methylsulfanyl-2-propylimidazole-4-carboxylic acid Chemical compound CCCC1=NC(SC)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC=2C=CC=CC=2)C=C1 BFZNLNWLXDQTOV-UHFFFAOYSA-N 0.000 claims 1
- DXEYRYYTYCMEFZ-UHFFFAOYSA-N 3-[[4-[2-(cyclohexylmethylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-5-(difluoromethylsulfanyl)-2-propylimidazole-4-carboxylic acid Chemical compound CCCC1=NC(SC(F)F)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC2CCCCC2)C=C1 DXEYRYYTYCMEFZ-UHFFFAOYSA-N 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 150000005840 aryl radicals Chemical class 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 230000004089 microcirculation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- WZHRJGWXUCLILI-UHFFFAOYSA-N sulfonylcarbamic acid Chemical compound OC(=O)N=S(=O)=O WZHRJGWXUCLILI-UHFFFAOYSA-N 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract description 19
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 6
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 150000002367 halogens Chemical class 0.000 abstract description 3
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 95
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 67
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 64
- 239000000243 solution Substances 0.000 description 59
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
- 238000002329 infrared spectrum Methods 0.000 description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 47
- 238000003756 stirring Methods 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 45
- 239000000203 mixture Substances 0.000 description 45
- 239000000284 extract Substances 0.000 description 37
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 34
- 239000000377 silicon dioxide Substances 0.000 description 33
- 239000000460 chlorine Substances 0.000 description 32
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 239000003480 eluent Substances 0.000 description 30
- 238000010992 reflux Methods 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 239000012429 reaction media Substances 0.000 description 22
- 235000011121 sodium hydroxide Nutrition 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 20
- 230000008569 process Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 238000004364 calculation method Methods 0.000 description 13
- 125000001072 heteroaryl group Chemical group 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 13
- 238000004454 trace mineral analysis Methods 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 11
- 239000002131 composite material Substances 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 125000005110 aryl thio group Chemical group 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 150000003462 sulfoxides Chemical class 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- 239000011591 potassium Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 150000003457 sulfones Chemical class 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 238000002211 ultraviolet spectrum Methods 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 241001024304 Mino Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 125000004149 thio group Chemical group *S* 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 101100452236 Caenorhabditis elegans inf-1 gene Proteins 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000002681 magnesium compounds Chemical class 0.000 description 4
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- OQURWGJAWSLGQG-UHFFFAOYSA-N 1-isocyanatopropane Chemical compound CCCN=C=O OQURWGJAWSLGQG-UHFFFAOYSA-N 0.000 description 3
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000031709 bromination Effects 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 150000004965 peroxy acids Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- QTWKINKGAHTPFJ-UHFFFAOYSA-N 2-(butan-2-yldisulfanyl)butane Chemical compound CCC(C)SSC(C)CC QTWKINKGAHTPFJ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IYJBSJSXRJQHRK-UHFFFAOYSA-N 2-butyl-5-methylsulfanyl-1h-imidazole Chemical compound CCCCC1=NC(SC)=CN1 IYJBSJSXRJQHRK-UHFFFAOYSA-N 0.000 description 2
- MKBBSFGKFMQPPC-UHFFFAOYSA-N 2-propyl-1h-imidazole Chemical compound CCCC1=NC=CN1 MKBBSFGKFMQPPC-UHFFFAOYSA-N 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical class N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- XYONNSVDNIRXKZ-UHFFFAOYSA-N S-methyl methanethiosulfonate Chemical compound CSS(C)(=O)=O XYONNSVDNIRXKZ-UHFFFAOYSA-N 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229910052776 Thorium Inorganic materials 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 2
- GVPWHKZIJBODOX-UHFFFAOYSA-N dibenzyl disulfide Chemical compound C=1C=CC=CC=1CSSCC1=CC=CC=C1 GVPWHKZIJBODOX-UHFFFAOYSA-N 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- 125000005544 phthalimido group Chemical group 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 150000003385 sodium Chemical class 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- WAAPEIZFCHNLKK-UFBFGSQYSA-N (2s,4s)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide Chemical compound C([C@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-UFBFGSQYSA-N 0.000 description 1
- KLVDUSUYBDMJKR-SANMLTNESA-N (6s)-1-[(4-amino-3-methylphenyl)methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound C1=C(N)C(C)=CC(CN2C=3C[C@H](N(CC=3N=C2)C(=O)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C(O)=O)=C1 KLVDUSUYBDMJKR-SANMLTNESA-N 0.000 description 1
- ABFQGXBZQWZNKI-UHFFFAOYSA-N 1,1-dimethoxyethanol Chemical compound COC(C)(O)OC ABFQGXBZQWZNKI-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MSYLETHDEIJMAF-UHFFFAOYSA-N 2,2-diphenylacetyl chloride Chemical compound C=1C=CC=CC=1C(C(=O)Cl)C1=CC=CC=C1 MSYLETHDEIJMAF-UHFFFAOYSA-N 0.000 description 1
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 1
- JCGGPCDDFXIVQB-UHFFFAOYSA-N 2,4,5-tribromo-1h-imidazole Chemical compound BrC1=NC(Br)=C(Br)N1 JCGGPCDDFXIVQB-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- PHYQYPWFGPJYDR-UHFFFAOYSA-N 2-[(4,5-dibromo-2-propylimidazol-1-yl)methoxy]ethyl-trimethylsilane Chemical compound CCCC1=NC(Br)=C(Br)N1COCC[Si](C)(C)C PHYQYPWFGPJYDR-UHFFFAOYSA-N 0.000 description 1
- GJHBARRNAWMGPQ-UHFFFAOYSA-N 2-[2-butyl-5-methylsulfanyl-3-[[4-[2-(phenylmethoxycarbonylsulfamoyl)phenyl]phenyl]methyl]imidazol-4-yl]-2-hydroxypropanoic acid Chemical compound CCCCC1=NC(SC)=C(C(C)(O)C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)OCC=2C=CC=CC=2)C=C1 GJHBARRNAWMGPQ-UHFFFAOYSA-N 0.000 description 1
- ABGUYQYTMFLCKQ-UHFFFAOYSA-N 2-[3-[[4-[2-(benzylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-5-methylsulfanyl-2-propylimidazol-4-yl]-2-hydroxyacetic acid Chemical compound CCCC1=NC(SC)=C(C(O)C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC=2C=CC=CC=2)C=C1 ABGUYQYTMFLCKQ-UHFFFAOYSA-N 0.000 description 1
- DPQGKLYENQMMAB-UHFFFAOYSA-N 2-bromo-1-[2-butyl-5-methylsulfanyl-3-[(4-phenylphenyl)methyl]imidazol-4-yl]-2-methylsulfinylethanone Chemical group BrC(C(=O)C1=C(N=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1)CCCC)SC)S(=O)C DPQGKLYENQMMAB-UHFFFAOYSA-N 0.000 description 1
- BJVMBNDJJHSPIX-UHFFFAOYSA-N 2-butyl-3-[[4-[2-(cyclohexylmethylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-5-(difluoromethylsulfanyl)imidazole-4-carboxylic acid Chemical compound CCCCC1=NC(SC(F)F)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC2CCCCC2)C=C1 BJVMBNDJJHSPIX-UHFFFAOYSA-N 0.000 description 1
- APPXUHSHUNYXAJ-UHFFFAOYSA-N 2-butyl-3-[[4-[2-(cyclohexylmethylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-5-methylsulfanylimidazole-4-carboxylic acid Chemical compound CCCCC1=NC(SC)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC2CCCCC2)C=C1 APPXUHSHUNYXAJ-UHFFFAOYSA-N 0.000 description 1
- MXYVBQRGYRKDMJ-UHFFFAOYSA-N 2-butyl-5-methyl-1H-imidazole-4-carbothioic S-acid Chemical compound C(CCC)C=1NC(=C(N=1)C)C(=S)O MXYVBQRGYRKDMJ-UHFFFAOYSA-N 0.000 description 1
- JRMAQQQTXDJDNC-UHFFFAOYSA-M 2-ethoxy-2-oxoacetate Chemical compound CCOC(=O)C([O-])=O JRMAQQQTXDJDNC-UHFFFAOYSA-M 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BGJGZEMCQLWCLV-UHFFFAOYSA-N 3-[[4-[2-(benzylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-2-butyl-5-(difluoromethylsulfanyl)imidazole-4-carboxylic acid Chemical compound CCCCC1=NC(SC(F)F)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC=2C=CC=CC=2)C=C1 BGJGZEMCQLWCLV-UHFFFAOYSA-N 0.000 description 1
- UWYCFIRXBWSITR-UHFFFAOYSA-N 3-[[4-[2-(benzylcarbamoylsulfamoyl)phenyl]phenyl]methyl]-5-bromo-2-propylimidazole-4-carboxylic acid Chemical compound CCCC1=NC(Br)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)S(=O)(=O)NC(=O)NCC=2C=CC=CC=2)C=C1 UWYCFIRXBWSITR-UHFFFAOYSA-N 0.000 description 1
- GQGGDXFYLXNVBG-UHFFFAOYSA-N 3-[[4-[2-(butoxycarbonylsulfamoyl)phenyl]phenyl]methyl]-5-methylsulfanyl-2-propylimidazole-4-carboxylic acid Chemical compound CCCCOC(=O)NS(=O)(=O)C1=CC=CC=C1C(C=C1)=CC=C1CN1C(C(O)=O)=C(SC)N=C1CCC GQGGDXFYLXNVBG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CUQPTVCVZLUXJB-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 CUQPTVCVZLUXJB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HSTIBAWDANLYRK-UHFFFAOYSA-N 4-methyl-n-sulfanylidenebenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=S)C=C1 HSTIBAWDANLYRK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FXZYUMRDZGHMFR-UHFFFAOYSA-N C(CCC)C=1N(C(=C(N1)SC)C(C(=O)O)=C)CC1=CC=C(C=C1)C1=C(C=CC=C1)S(=O)(=O)NC(=O)NCCC Chemical compound C(CCC)C=1N(C(=C(N1)SC)C(C(=O)O)=C)CC1=CC=C(C=C1)C1=C(C=CC=C1)S(=O)(=O)NC(=O)NCCC FXZYUMRDZGHMFR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- CETBSQOFQKLHHZ-UHFFFAOYSA-N Diethyl disulfide Chemical compound CCSSCC CETBSQOFQKLHHZ-UHFFFAOYSA-N 0.000 description 1
- LZAZXBXPKRULLB-UHFFFAOYSA-N Diisopropyl disulfide Chemical compound CC(C)SSC(C)C LZAZXBXPKRULLB-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000277306 Esocidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000238558 Eucarida Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 241001481824 Indri Species 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- UPFRWUMNXOAGDQ-UHFFFAOYSA-N NS(=O)(=O)C1=C(C=CC=C1)C1=CC=C(C=C1)CN1C(=CC2=C(C(=CC=C12)C(C(=O)O)(C)O)SC)CCCC Chemical compound NS(=O)(=O)C1=C(C=CC=C1)C1=CC=C(C=C1)CN1C(=CC2=C(C(=CC=C12)C(C(=O)O)(C)O)SC)CCCC UPFRWUMNXOAGDQ-UHFFFAOYSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 description 1
- 206010046763 Uterine atony Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- DBKNIEBLJMAJHX-UHFFFAOYSA-N [As]#B Chemical compound [As]#B DBKNIEBLJMAJHX-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 description 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- UBLYEVLMRSPMOG-UHFFFAOYSA-N cyclopentylmethanamine Chemical compound NCC1CCCC1 UBLYEVLMRSPMOG-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000004882 diastolic arterial blood pressure Effects 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- CIYGMWIAXRMHQS-UHFFFAOYSA-N ditert-butyl oxalate Chemical compound CC(C)(C)OC(=O)C(=O)OC(C)(C)C CIYGMWIAXRMHQS-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LCFXLZAXGXOXAP-DAXSKMNVSA-N ethyl (2z)-2-cyano-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(=N/O)\C#N LCFXLZAXGXOXAP-DAXSKMNVSA-N 0.000 description 1
- BMTHPXDFOIORGI-UHFFFAOYSA-N ethyl 2-oxoacetate;thiophene Chemical compound C=1C=CSC=1.CCOC(=O)C=O BMTHPXDFOIORGI-UHFFFAOYSA-N 0.000 description 1
- CKTYYUQUWFEUCO-UHFFFAOYSA-N ethyl 3-methyl-2-oxobutanoate Chemical compound CCOC(=O)C(=O)C(C)C CKTYYUQUWFEUCO-UHFFFAOYSA-N 0.000 description 1
- QKLCQKPAECHXCQ-UHFFFAOYSA-N ethyl phenylglyoxylate Chemical compound CCOC(=O)C(=O)C1=CC=CC=C1 QKLCQKPAECHXCQ-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NIXOIRLDFIPNLJ-UHFFFAOYSA-M magnesium;benzene;bromide Chemical compound [Mg+2].[Br-].C1=CC=[C-]C=C1 NIXOIRLDFIPNLJ-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- OPUAWDUYWRUIIL-UHFFFAOYSA-N methanedisulfonic acid Chemical compound OS(=O)(=O)CS(O)(=O)=O OPUAWDUYWRUIIL-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- ATFKBWNEVZUSKC-UHFFFAOYSA-N methyl 2-isocyanatobenzoate Chemical compound COC(=O)C1=CC=CC=C1N=C=O ATFKBWNEVZUSKC-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- YLHXLHGIAMFFBU-UHFFFAOYSA-N methyl phenylglyoxalate Chemical compound COC(=O)C(=O)C1=CC=CC=C1 YLHXLHGIAMFFBU-UHFFFAOYSA-N 0.000 description 1
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- DYFFAVRFJWYYQO-UHFFFAOYSA-N n-methyl-n-phenylaniline Chemical compound C=1C=CC=CC=1N(C)C1=CC=CC=C1 DYFFAVRFJWYYQO-UHFFFAOYSA-N 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- ZEJYUSNKPNYKPO-UHFFFAOYSA-N prop-1-ene Chemical compound CC=[CH-] ZEJYUSNKPNYKPO-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- QQKDTTWZXHEGAQ-UHFFFAOYSA-N propyl carbonochloridate Chemical compound CCCOC(Cl)=O QQKDTTWZXHEGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012260 resinous material Substances 0.000 description 1
- 239000012261 resinous substance Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical group [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. アンジオテンシンIIのAT1及びAT2レセプターの異常な刺激から生じる 疾病の治療のための製薬組成物の製造のために、次式(I) [ここで、 R1は多くとも6個の炭素原子を含有する線状若しくは分岐状のアルキル、ア ルキルチオ及びアルコキシ基、アリール、アリールチオ若しくはアリールオキシ 基又はアリールアルキル基(アルキル基は線状若しくは分岐状であって、多くと も6個の炭素原子を含有する。)を表わし、 R2は (ここで、Rは多くとも8個の炭素原子を含有する線状若しくは分岐状のアルキ ル若しくはアルケニル基、多くとも6個の炭素原子を含有するシクロアルキル基 又はア リール基を表わす。このアルキル、アルケニル、シクロアルキル及びアリール基 はハロゲン原子、ヒドロキシル、多くとも6個の炭素原子を含有する線状若しく は分岐状のアルコキシ及びアルキルチオ基並びにフェニル基(これ自体ハロゲン 原子、ヒドロキシル基及び多くとも6個の炭素原子を含有する線状若しくは分岐 状のアルコキシ基から選択される1個以上の基により置換されていてもよい。) から選択される1個以上の基により置換されていてもよい。) の基、 b)ハロゲン原子、又は (ここで、Zはヒドロキシル、アルコキシ又は遊離の、塩形成若しくはエステル 化されたカルボキシ基を表わす。) の基 を表わし、 R3は −遊離の、塩形成又はエステル化されたカルボキシ基、 −アシル基(フェニル、チエニル又はテトラゾリル基により置換されていてもよ い。)、 −ハロゲン原子、 −多くとも8個の炭素原子を含有する線状又は分岐状の アルキル、アルケニル又はアルキルチオ基 から選択され、 これらの基は、ハロゲン原子、下記の基: ・ヒドロキシル、アルコキシ、アシル若しくはアリール、 ・遊離の、塩形成、エステル化若しくはアミド化されたカルボキシ基、 ・次式 {ここで、R6及びR7又はR8及びR9は同一であっても異なっていてもよく、次 の群: ・水素原子、 ・多くとも6個の炭素原子を含有するアシル、アルキル及びアルケニル基、ア ルキルスルホニル及びアリールスルホニル基(これらの基はハロゲン原子、ヒド ロキシル基、多くとも6個の炭素原子を含有するアルコキシ基又は遊離の、塩形 成若しくはエステル化されたカルボキシ基から選択される同一又は異なった1個 以上の基により置換されていてもよい。)、 ・アリール、アリールアルキル及びアリールアルケニル基(これらの基におい て線状又は分岐状のアルキル及びアルケニル基は多くとも6個の炭素原子を含有 する。これらのアリール、アリールアルキル及びアリールアル ケニル基はハロゲン原子、ヒドロキシル及びニトロ基、多くとも6個の炭素原子 を含有するアルキル、アルケニル、ハロアルキル、アルコキシ及びアリール基、 アミノ基(多くとも6個の炭素原子を含有する1若しくは2個の同一若しくは異 なったアルキル基により置換されていてもよい。)並びに遊離の、塩形成若しく はエステル化されたカルボキシ基から選択される1個以上の基により置換されて いてもよい。) から選択されるか、或いは 一方のR6及びR7並びに他方のR8及びR9は、それぞれ、それらが結合してい る窒素原子と一緒になって次の基:イミダゾリル、ピロリル、ピロリニル、ピロ リジニル、ピペリジニル、ピリミジニル、ピリダジニル、ピペラジニル、フェニ ルピペラジニル、オキサゾリル、モルホリニル、チオモルホリニル、アゼビン及 びインドリル基(これらの基はハロゲン原子、ヒドロキシル基、トリフルオルメ チル基、多くとも6個の炭素原子を含有するアルキル及びアルコキシ基から選択 される1個以上の同一又は異なった基により置換されていてもよい。) から選択される複素環式基を形成するか、或いは R8及びR9は同一であっても異なっていてもよく、アミノ酸を表わし、或いは R8又はR9の一方はカルバモイル、アルコキシカルボニル又はベンジルオキシカ ルボニル基を表わし、或いはR8及びR9はそれらが結合している窒素原子と一緒 になってフタルイミド又はスク シンイミド基を形成する。} の基 から選択される1個以上の基により置換されていてもよく、 R4は a)下記の基: (ここで、Dは酸素又は硫黄原子を表わす。) のいずれか、 b)−SO2−W−R14基(ここで、Wは−NR15−、−NH−CO−、−NH −CO−O−、−N=CH−NR15−又は−NH−CO−NR15−基を表わし、 これらの基においてR14及びR15は同一であっても異なっていてもよく、水素原 子、多くとも8個の炭素原子を含有する線状若しくは分岐状のアルキル若しくは アルケニル基、多くとも6個の炭素原子を含有するシクロアルキル基 及びアリール基から選択され、このアルキル、アルケニル、シクロアルキル及び アリール基はハロゲン原子、次の基:ヒドロキシル基、多くとも4個の炭素原子 を含有するアルコキシ、ニトロ、シアノ、アミノ、モノ及びジアルキルアミノ、 遊離の、塩形成若しくはエステル化されたカルボキシ、ハロアルキル、アルキル チオ、ハロアルキルチオ、ハロアルコキシ、カルバモイル、アシル、アシルオキ シ、シクロアルキル、シクロアルケニル、アリール、フェニルチオ、ピリジル、 テトラゾリル、チエニル、ニトロピリジル、ピリミジニル、ジアゾリル、ピペリ ジニル、アルキルピペリジニル、チアゾリル、アルキルチオアゾリル、テトラヒ ドロフラニル及びメチルテトラヒドロフラニル基(ハロゲン原子及びヒドロキシ ル若しくは多くとも4個の炭素原子を含有するアルコキシ基から選択される1個 以上の基により置換されていてもよい。)から選択される1個以上の基により置 換されていてもよく、或いはR14及びR15はそれらが結合している窒素原子と一 緒になって次の基:ピロリル、ピロリニル、ピロリジニル、ピペラジニル、アル キルピペラジニル、フェニルピペラジニル、モルホリニル及びインドリル基から 選択される基を形成する。) を表わす。 式(I)の化合物におけるアルキル基は酸素、硫黄及び窒素原子から選択され る1個以上の複素原子によって中断されていてよく、また式(I)の化合物にお ける硫 黄原子はスルホン又はスルホキシドの形で酸化されていてもよい。] の化合物[式(I)の化合物はその全ての可能なラセミ、エナンチオマー及びジ アステレオマー型異性体の形態にあり得る。]並びに式(I)の化合物の無機及 び有機酸又は無機及び有機塩基との付加塩の使用。 2. 次式(IA) [ここで、 R1Aは多くとも6個の炭素原子を含有する線状若しくは分岐状のアルキル又は アルキルチオ基を表わし、 R2Aは (ここで、RAは多くとも8個の炭素原子を含有する線状若しくは分岐状のアル キル若しくはアルケニル基、シクロアルキル基又はアリール基を表わす。これら の基はハロゲン原子、特に弗素原子から選択される1個以上の基により置換され ていてもよい。) の基、 b)ハロゲン原子、又は (ここで、Zは遊離の、塩形成若しくはエステル化されたカルボキシ基を表わす ) の基 を表わし、 R3Aは −遊離の、塩形成、エステル化又はアミド化されたカルホキシ基、 −ホルミル及びアセチル基(フェニル、ベンジル、フェネチル又はテトラゾリル 基により置換されていてもよい。)、 −ハロケン原子、 −多くとも8個の炭素原子を含有する線状又は分岐状のアルキル、アルケニル又 はアルキルチオ基(これらの基は次の基:ヒドロキシ、アルコキシ、アシル、フ ェニル、遊離の、塩形成、エステル化若しくはアミド化されたカルボキシ、カル バモイル及びアミノ基(窒素原子上に次の基:多くとも6個の炭素原子を含有す るアルキル、アシル、アルキルスルホニル、フェニルスルホニル、フェニル及び フェニルアルキルから選択される1又は2個の基が置換していてもよい。これら の基はハロゲン原子、ヒドロキシル基及び多くとも4個が線状若しくは分岐 状のアルコキシ基から選択される1個以上の基により置換されていてもよい。) から選択される1個以上の基により置換されていてもよい。) を表わし、 R4AはSO2−WA−R16A基(ここで、WAは−NH−、−NH−CO−、−N H−CO−O−、 表わし、R16A及びR17Aは水素原子、多くとも4個の炭素原子を含有する線状若 しくは分岐状のアルキル若しくはアルケニル基又はアリール基を表わし、これら の基はハロゲン原子、次の基:ヒドロキシル、多くとも4個の炭素原子を含有す るアルコキシ、ニトロ、シアノ、アミノ、モノ−及びジアルキルアミノ、遊離の 、塩形成若しくはエステル化されたカルボキシ、シクロヘキシル、シクロヘキセ ニル、ピリジル、チエニル及びフェニル基(これらの基はハロゲン原子、ヒドロ キシル又は多くとも4個の炭素原子を含有するアルコキシ基により置換されてい てもよい。)から選択される1個以上の基により置換されていてもよい。)を表 わす。 なお、式(IA)の化合物における硫黄原子はスルホン又はスルホキシドの形 で酸化されていてもよい。] の化合物[式(IA)の化合物はその全ての可能なラセミ、エナンチオマー及び ジアステレオマー型異性体の形態にあり得る。]並びに式(IA)の化合物の無 機及び有機 酸又は無機及び有機塩基との付加塩に相当する請求項1に記載の式(I)の化合 物の使用。 3. 下記の式(I)の化合物: ・2−ブチル−1−[(2'−(((((シクロヘキシルメチル)アミノ)カルボ ニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メチル]−4 −(メチルチオ)−1H−イミダゾール−5−カルボン酸 ・2−ブチル−4−(メチルチオ)−1−[(2'−(((((フェニルメチル) アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル )メチル]−1H−イミダゾール−5−カルボン酸 ・2−ブチル−4−(メチルチオ)−1−[(2'−(((((1−β−フェニル プロピル)アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェニル) −4−イル)メチル]−1H−イミダゾール−5−カルボン酸 ・2−ブチル−4−(メチルチオ)−1−[(2'−(((((1−(4−フェニ ルブチル))アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェニル )−4−イル)メチル]−1H−イミダゾール−5−カルボン酸 ・2−ブチル−1−[(2'−((((((4−メトキシ)フェニルメチル)アミ ノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メ チル]−4−メチルチオ−1H−イミダゾール−5−カルボン酸 ・2−ブチル−1−[(2'−((((((4−フルオル)フェニルメチル)アミ ノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メ チル]−4−メチルチオ−1H−イミダゾール−5−カルボン酸 ・2−ブチル−1−[(2'−(((((1−(1−カルボキシ−2−フェニル) エチル)アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェニル)− 4−イル)メチル]−4−メチルチオ−1H−イミダゾール−5−カルボン酸 ・2−ブチル−4−(メチルチオ)−1−[(2'−((((2−チエニル)メト キシカルボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メ チル]−1H−イミダゾール−5−カルボン酸 ・2−ブチル−4−(メチルチオ)−1−[(2'−((((3−チエニル)メト キシカルボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メ チル]−1H−イミダゾール−5−カルボン酸 ・2−ブチル−1−[(2'−((((シクロヘキセン−4−イル)メトキシカル ボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メチル]− 4−メチルチオ−1H−イミダゾール−5−カルボン酸 ・2−ブチル−1−[(2'−((((シクロヘキシル)メトキシカルボニル)ア ミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メチル]−4−メチル チオ− 1H−イミダゾール−5−カルボン酸 ・2−ブチル−4−(メチルチオ)−1−[(2'−(((フェニルメトキシカル ボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メチル]− 1H−イミダゾール−5−カルボン酸 ・((4’−((2−ブチル−5−ホルミル−4−メトキシ−1H−イミダゾー ル−1−イル)メチル)(1,1'−ビフェニル)−2−イル)スルホニル)カル バミン酸(フェニルメチル) のいずれかである請求項1に記載の使用。 4. 次式(IB) [ここで、 R1Bは多くとも4個の炭素原子を含有する線状又は分岐状のアルキル基を表わ し、 R2Bは多くとも4個の炭素原子を含有する線状又は分岐状のアルキルチオ基( 1個以上の弗素原子により置換されていてもよい。)を表わし、 R3Bは −遊離の、塩形成、エステル化又はアミド化されたカル ボキシ基を表わし、 −アシル、カルバモイル基、 −多くとも6個の炭素原子を含有するアルキル及びアルケニル基(これらはハロ ゲン原子、次の基:ヒドロキシ、アルコキシ、遊離の、塩形成、エステル化若し くはアミド化されたカルボキシ、フェニル及びカルバモイル基(フェニル又はベ ンジル基により置換されていてもよい。)から選択される1個以上の基により置 換されている。) を表わし、 (ここで、Lは−O−又は−NH−を表わす。) の一つを表わす。 なお、式(IB)の化合物における硫黄原子はスルホン又はスルホキシドの形 で酸化されていてもよい。] の化合物[式(IB)の化合物はその全ての可能なラセミ、エナンチオマー及び ジアステレオマー型異性体の形態にあり得る。]並びに式(IB)の化合物の無 機及び有機酸又は無機及び有機塩基との付加塩。 5. 下記の化学式: ・2−ブチル−α−ヒドロキシ−α−メチル−4−(メチルチオ)−1−[(2' −((((フェニルメトキシ)カルボニル)アミノ)スルホニル)(1,1'−ビ フェニル)−4−イル)メチル]−1H−イミダゾール−5−酢酸 ・2−ブチル−α−ヒドロキシ−α−メチル−4−(メチルチオ)−1−[(2' −((((プロピルアミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフ ェニル)−4−イル)メチル]−1H−イミダゾール−5−酢酸 ・2−ブチル−α−ヒドロキシ−α−メチル−4−(メチルチオ)−1−[(2' −(((((フェニルメチル)アミノ)カルボニル)アミノ)スルホニル)(1 ,1'−ビフェニル)−4−イル)メチル]−1H−イミダゾール−5−酢酸 ・2−ブチル−1−[(2'−(((((シクロヘキシル メチル)アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェニル)− 4−イル)メチル]−α−ヒドロキシ−α−メチル−4−(メチルチオ)−1H −イミダゾール−5−酢酸 ・1−[(2'−(((フェニルメチル)アミノ)スルホニル)(1,1'−ビフェ ニル)−4−イル)メチル]−α−ヒドロキシ−4−(メチルチオ)−2−プロ ピル−1H−イミダゾール−5−酢酸 ・1−[(2'−(((((シクロヘキシルメチル)アミノ)カルボニル)アミノ )スルホニル)(1,1'−ビフェニル)−4−イル)メチル]−4−(メチルチ オ)−2−プロピル−1H−イミダゾール−5−カルボン酸ナトリウム ・4−(メチルチオ)−1−[(2'−(((((フェニルメチル)アミノ)カル ボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イル)メチル]− 2−プロピル−1H−イミダゾール−5−カルボン酸 ・α−ブチル−α−ヒドロキシ−4−(メチルチオ)−1−[(2'−((((( フェニルメチル)アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェ ニル)−4−イル)メチル]−2−プロピル−1H−イミダゾール−5−酢酸ナ トリウム ・α−ヒドロキシ−4−(メチルチオ)−α−フェニル−1−((2'−(((( (フェニルメチル)アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフ ェニル )−4−イル)メチル)−2−プロピル−1H−イミダゾール−5−酢酸 ・1−((2'−(((((シクロヘキシルメチル)アミノ)カルボニル)アミノ )スルホニル)(1,1'−ビフェニル)−4−イル)メチル)−4−((ジフル オルメチル)チオ)−2−プロピル−1H−イミダゾール−5−カルボン酸 ・4−((ジフルオルメチル)チオ)−1−((2'−(((((フェニルメチル )アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビフェニル)−4−イ ル)メチル)−2−プロピル−1H−イミダゾール−5−カルボン酸 ・4−((ジフルオルメチル)チオ)−2−プロピル−1−((2'−((((( 2−チエニルメチル)アミノ)カルボニル)アミノ)スルホニル)(1,1'−ビ フェニル)−4−イル)メチル)−1H−イミダゾール−5−カルボン酸 のいずれかに相当する請求項4に記載式(IB)の化合物。 6. 請求項1及び4に記載の式(I)の化合物を製造するにあたり、 −次式(II) (ここで、R'1はR1について前記した意味を有するが、その存在し得る反応性 官能基は保護基により保護されていてよい。Pは窒素原子の保護基を表わす。) の化合物をハロゲン化反応に付して次式(III) (ここで、R'1及びPは前記の意味を有し、Halはハロゲン原子を表わす。) の化合物を得、この化合物をハロゲン原子の1個についてハロゲン−金属交換反 応に付し、次いで次式(IVa)、(IVb)、(IVc)、(IVd)又は(IVe) (ここで、R’はRについて前記した意味を有するが、その存在し得る反応性官 能基は保護基により保護されていてよい。alkは多くとも4個の炭素原子を含 有する アルキル基を表わす。) の化合物と反応させて次式(V) (ここで、R'1、P及びHalは前記した意味を有し、R"3は前記のようなS− R’又はK−O−alk(Kは の化合物を得、式(V)の化合物をハロゲン原子についてハロゲン−金属交換反 応に付し、次いで次式(IV'a)、(IV'b)、(IV'c)、(IV'd)又は(IV'e) (ここで、R”はR’と同一であっても異なっていてもよく、Rについて前記し た意味を有するが、その存在し得る反応性官能基は保護基により保護されていて よい。alk’はalkと同一であっても異なっていてよく、多くとも4個の炭 素原子を含有するアルキル基を表わす。) の化合物と反応させて次式(VII) (ここで、R'1及びPは前記した意味を有し、R"2及びR"3は同一であっても異 なっていてよく、前記のような−S−R’、−S−R”、−K−O−alk又は −K−O−alk’(R’、R”、alk、alk’及びKは前記した意味を有 する。)を表わす。) の化合物を得、この式(VII)の化合物から上記のようなPによりブロックされ たアミン官能基を遊離化し、次いで次式(VIII) (ここで、R'4はR4について前記した意味を有するが、その存在し得る反応性 官能基は保護基により保護されていてよい。Halはハロゲン原子を表わす。) の化合物と反応させて次式(I1) (ここで、R'1、R"2、R"3及びR'4は前記した意味を有する) の化合物を得るか、或いは −次式(IX) (ここで、R'1は前記の意味を有し、Mは水素原子又はR'2基(これはR2につ いて前記した意味を有するが、その存在し得る反応性官能基は保護基により保護 されていてよい。)を表わす。) の化合物に前記した式(VIII)の化合物を反応させて次式(X) (ここで、R'1、M及びR'4は前記の意味を有する。)の化合物を得、式(X) の化合物をMが前記のようなR'2を表わすときはハロゲン化反応に付して次式( XI) (ここで、R'1、R'2、R'4及びHalは前記の意味を有する。) の化合物を得、この化合物をハロゲン−金属交換反応に付し、次いで次式(XII ) (ここで、R'10はR10について前記した意味を有するが、その存在し得る反応 性官能基は保護基により保護されていてよい。) の化合物と反応させて次式(I2) (ここで、R'1、R'2、R'4及びR'10は前記の意味を有する。) の化合物を得、 −式(I2)の化合物をけん化反応に付して次式(I4) (ここで、R'1、R'2、R'4及びR'10は前記の意味を有する。) の化合物を得、 −式(X)の化合物をMが水素原子を表わすときはハロゲン化反応に付して次式 (XIV) (ここで、R'1、R'4及びHalは前記の意味を有する。) の化合物を得、この化合物をハロゲン−金属交換反応に付し、次いで前記のよう な式(IVa)、(IVb)、(IVc)、(IVd)又は(IVe)の化合物を作用させて次式(I7) (ここで、R'1、R'4、Hal及びR"3は前記の意味を有する。) の化合物を得、この式(I7)の化合物をハロゲン−金属交換反応に付し、次い で前記のような式(IV'a)、(IV'b)、(IV'c)、(IV'd)又は(IV'e)の化合 物を作用させて次式(I8) (ここで、R'1、R'4、R"2及びR"3は前記の意味を有する。) の化合物を得るか、或いは −次式(XX) (ここで、R'1及びR'2は前記の意味を有し、R'3はR3について前記した意味 を有するが、その存在し得る反応性官能基は保護基により保護されていてよい。 ) の化合物に前記のような式(VIII)の化合物を反応させて次式(I') (ここで、R'1、R'2、R'3及びR'4は前記の意味を有する。) の化合物を得、 前記の式(I1)、(I2)、(I3)、(I4)、(I5)、(I6)、(I7)、(I8)及び(I' )の化合物は式(I)の化合物である場合があるが、次いで、式(I)の化合物 又はその他の化合物を得るために、所望ならば及び必要ならば、これらの化合物 を下記の転化反応: a)酸官能基のエステル化、 b)エステル官能基の酸官能基へのけん化、 c)エステル官能基のアシル官能基への転化、 d)シアノ官能基の酸官能基への転化、 e)酸官能基のアミド官能基への転化、次いで要すればチオアミド官能基への転 化、 f)カルボキシ官能基のアルコール官能基への還元、 g)アルコキシ官能基のヒドロキシル官能基への転化、又はヒドロキシ官能基の アルコキシ官能基への転化、 h)アルコール官能基のアルデヒド、酸又はケトン官能基への酸化、 i)ホルミル基のカルバモイル基への転化、 j)カルバモイル基のニトリルへの転化、 k)ニトリル基のテトラゾリル基への転化、 l)アルキルチオ又はアリールチオ基の対応するスルホキシド又はスルホンへの 酸化、 m)スルフィド、スルホキシド又はスルホン官能基の相当するスルホキシミン官 能基への転化、 n)オキソ官能基のチオキソ官能基への転化、 o)ヒドロキシアルキル基のアルケニル基への脱水、 p)酸官能基の q)β−ケト−スルホキシド官能基のα−ケト−チオエステル官能基への転化、 r)カルバメートの尿素への転化、特にスルホニルカルバメートのスルホニル尿 素への転化、 s)保護された反応性官能基により支持され得る保護基の除去、 t)無機又は有機酸又は塩基により塩形成して相当する塩を得る反応、 u)ラセミ体の分割された化合物への分割 の一つ以上の反応に任意の順序で付する(このようにして得られた式(I)の化 合物はその全ての可能なラセミ、エナンチオマー及びジアステレオマー型異性体 の形態にあり得る。)ことを特徴とする式(I)の化合物並びにそれらの塩類の 製造法。 7. 請求の範囲4に記載の式(IB)の化合物[この式(IB)の化合物はその全て の可能なラセミ、エナンチオマー及びジアステレオマー型異性体の形態にあり得 る。]並びに式(IB)の化合物の製薬上許容できる無機及び有機酸又は無機及び 有機塩基との付加塩よりなる薬剤。 8. 請求の範囲5に記載の式(IB)の化合物並びに式 (IB)の化合物の製薬上許容できる無機及び有機酸又は無機及び有機塩基との付 加塩よりなる薬剤。 9. 請求の範囲4又は5に記載の薬剤の少なくとも1種を活性成分として含有 する製薬組成物。 10. アンジオテンシンIIのAT1及び(又は)AT2レセプターの異常な刺激 から生じる疾病の治療を意図した製薬組成物の製造への請求の範囲4に記載の式 (IB)の化合物の使用。 11. 動脈高血圧、心筋梗塞後、心不全及び血管形成後の狭窄の再発の治療を 意図した製薬組成物の製造への請求の範囲1〜5のいずれかに記載の式(I)、 (IA)及び(IB)の化合物の使用。 12. 腎不全の治療を意図した製薬組成物の製造への請求の範囲1〜5のいず れかに記載の式(I)、(IA)及び(IB)の化合物の使用。 13. 心臓血管障害、特に糖尿病が関係した微小循環障害の治療及び予防を意 図した製薬組成物の製造への請求の範囲1〜5のいずれかに記載の式(I)、( IA)及び(IB)の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR94/02518 | 1994-03-04 | ||
FR9402518A FR2716882B1 (fr) | 1994-03-04 | 1994-03-04 | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
PCT/FR1995/000228 WO1995023792A1 (fr) | 1994-03-04 | 1995-02-27 | Utilisation de derives de l'imidazole au traitement d'affections impliquant les recepteurs at1 et at2 de l'angiotensine, certains de ces produits, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09509926A true JPH09509926A (ja) | 1997-10-07 |
JP3881374B2 JP3881374B2 (ja) | 2007-02-14 |
Family
ID=9460689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52272795A Expired - Fee Related JP3881374B2 (ja) | 1994-03-04 | 1995-02-27 | アンジオテンシンのat1及びat2レセプターが関係する疾病の治療に有用なイミダゾール誘導体、それらの製造及びそれらの薬剤としての用途 |
Country Status (16)
Country | Link |
---|---|
US (2) | US5811445A (ja) |
EP (2) | EP1233015A1 (ja) |
JP (1) | JP3881374B2 (ja) |
KR (1) | KR100369425B1 (ja) |
CN (1) | CN1146765A (ja) |
AT (1) | ATE257471T1 (ja) |
AU (1) | AU704897B2 (ja) |
CA (1) | CA2184111A1 (ja) |
DE (1) | DE69532412T2 (ja) |
DK (1) | DK0748315T3 (ja) |
ES (1) | ES2210285T3 (ja) |
FR (1) | FR2716882B1 (ja) |
HU (1) | HUT75697A (ja) |
PT (1) | PT748315E (ja) |
RU (1) | RU2141321C1 (ja) |
WO (1) | WO1995023792A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002544130A (ja) * | 1999-05-05 | 2002-12-24 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アンギオテンシン(1−7)受容体のアゴニストとしての1−(p−チエニルベンジル)イミダゾール、その製造方法、その使用およびそれらを包含する医薬製剤 |
JP2011518884A (ja) * | 2008-04-29 | 2011-06-30 | セラヴァンス, インコーポレーテッド | 二重活性抗高血圧剤 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2716883B1 (fr) * | 1994-03-04 | 1996-04-26 | Roussel Uclaf | Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant. |
FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
EP0855392A3 (de) | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19832428A1 (de) | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19832429A1 (de) * | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
NZ587909A (en) * | 1998-12-23 | 2012-05-25 | Novartis Ag | Process of making a compressed tablets containing valsartan and microcrystalline cellulose |
US6465502B1 (en) | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
EP1013273A1 (en) * | 1998-12-23 | 2000-06-28 | Novartis AG | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
RU2298405C2 (ru) * | 1999-01-26 | 2007-05-10 | Новартис Аг | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда |
CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
DE10030087B4 (de) * | 2000-06-19 | 2007-01-18 | Boehringer Werkzeugmaschinen Gmbh | Verfahren und Vorrichtung zum Vermessen und Bearbeiten von Werkstücken |
DE60222409T2 (de) | 2001-05-31 | 2008-09-25 | Vicore Pharma Ab | Trizyklische verbindungen, nützlich als angiotensin ii agonisten |
KR20040022238A (ko) * | 2001-08-09 | 2004-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제 |
PE20040167A1 (es) * | 2002-03-28 | 2004-05-26 | Novartis Ag | Amidas del acido sulfamico |
CA2617055A1 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity |
EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
RU2475243C1 (ru) * | 2012-02-16 | 2013-02-20 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | Средство, обладающее антигипертензивной активностью |
EP4007592A1 (en) | 2019-08-02 | 2022-06-08 | LanthioPep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
GB2605148A (en) * | 2021-03-23 | 2022-09-28 | Vicore Pharma Ab | New compounds |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR465368A (fr) * | 1912-11-28 | 1914-04-15 | Franz Roemer | Procédé et appareil pour le séchage de placages et autres objets ayant la forme de feuilles ou de lames |
CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
EP0409332A3 (en) * | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
ES1011809Y (es) * | 1989-10-23 | 1991-08-01 | Minano Iglesias Jesus | Muneco-envase. |
DE3937182A1 (de) * | 1989-11-08 | 1991-05-16 | Bosch Gmbh Robert | Verfahren zur bearbeitung der oberflaeche von plankommutatoren |
IL98319A (en) * | 1990-07-05 | 1997-04-15 | Roussel Uclaf | Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them |
US5126342A (en) * | 1990-10-01 | 1992-06-30 | Merck & Co., Inc. | Imidazole angiotensin ii antagonists incorporating acidic functional groups |
CA2093125C (en) * | 1990-10-02 | 2003-12-16 | Warner-Lambert Company | Angiotensin ii antagonists |
CA2058198A1 (en) * | 1991-01-04 | 1992-07-05 | Adalbert Wagner | Azole derivatives, process for their preparation, and their use |
EP0505098A1 (en) * | 1991-03-19 | 1992-09-23 | Merck & Co. Inc. | Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists |
TW215434B (ja) * | 1992-03-07 | 1993-11-01 | Hoechst Ag | |
EP0577023A3 (en) * | 1992-07-01 | 1996-12-18 | Hoechst Ag | Angiotensin-ii receptor-antagonists for the treatment of arrhythmices |
EP0577025A3 (de) * | 1992-07-01 | 1998-02-04 | Hoechst Aktiengesellschaft | Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen |
JP3309438B2 (ja) * | 1992-09-04 | 2002-07-29 | 日本ゼオン株式会社 | ブロック共重合体 |
FR2711367B1 (fr) * | 1993-10-19 | 1995-12-01 | Roussel Uclaf | Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus. |
US5395844A (en) * | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
-
1994
- 1994-03-04 FR FR9402518A patent/FR2716882B1/fr not_active Expired - Fee Related
-
1995
- 1995-02-27 CA CA002184111A patent/CA2184111A1/fr not_active Abandoned
- 1995-02-27 CN CN95192744A patent/CN1146765A/zh active Pending
- 1995-02-27 ES ES95910603T patent/ES2210285T3/es not_active Expired - Lifetime
- 1995-02-27 AT AT95910603T patent/ATE257471T1/de not_active IP Right Cessation
- 1995-02-27 AU AU18524/95A patent/AU704897B2/en not_active Ceased
- 1995-02-27 JP JP52272795A patent/JP3881374B2/ja not_active Expired - Fee Related
- 1995-02-27 PT PT95910603T patent/PT748315E/pt unknown
- 1995-02-27 EP EP02006541A patent/EP1233015A1/fr not_active Withdrawn
- 1995-02-27 EP EP95910603A patent/EP0748315B1/fr not_active Expired - Lifetime
- 1995-02-27 HU HU9602414A patent/HUT75697A/hu unknown
- 1995-02-27 RU RU96120211A patent/RU2141321C1/ru active
- 1995-02-27 WO PCT/FR1995/000228 patent/WO1995023792A1/fr active IP Right Grant
- 1995-02-27 DE DE69532412T patent/DE69532412T2/de not_active Expired - Fee Related
- 1995-02-27 US US08/700,468 patent/US5811445A/en not_active Expired - Fee Related
- 1995-02-27 KR KR1019960704848A patent/KR100369425B1/ko not_active IP Right Cessation
- 1995-02-27 DK DK95910603T patent/DK0748315T3/da active
-
1998
- 1998-06-01 US US09/088,156 patent/US5977155A/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002544130A (ja) * | 1999-05-05 | 2002-12-24 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アンギオテンシン(1−7)受容体のアゴニストとしての1−(p−チエニルベンジル)イミダゾール、その製造方法、その使用およびそれらを包含する医薬製剤 |
JP2011518884A (ja) * | 2008-04-29 | 2011-06-30 | セラヴァンス, インコーポレーテッド | 二重活性抗高血圧剤 |
Also Published As
Publication number | Publication date |
---|---|
RU2141321C1 (ru) | 1999-11-20 |
AU1852495A (en) | 1995-09-18 |
EP1233015A1 (fr) | 2002-08-21 |
WO1995023792A1 (fr) | 1995-09-08 |
US5811445A (en) | 1998-09-22 |
JP3881374B2 (ja) | 2007-02-14 |
PT748315E (pt) | 2004-05-31 |
CA2184111A1 (fr) | 1995-09-08 |
EP0748315A1 (fr) | 1996-12-18 |
ES2210285T3 (es) | 2004-07-01 |
CN1146765A (zh) | 1997-04-02 |
HU9602414D0 (en) | 1996-11-28 |
AU704897B2 (en) | 1999-05-06 |
US5977155A (en) | 1999-11-02 |
DK0748315T3 (da) | 2004-03-15 |
DE69532412D1 (de) | 2004-02-12 |
KR970701700A (ko) | 1997-04-12 |
KR100369425B1 (ko) | 2003-05-22 |
HUT75697A (en) | 1997-05-28 |
FR2716882B1 (fr) | 1996-04-05 |
EP0748315B1 (fr) | 2004-01-07 |
ATE257471T1 (de) | 2004-01-15 |
DE69532412T2 (de) | 2004-10-07 |
FR2716882A1 (fr) | 1995-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09509926A (ja) | アンジオテンシンのat1及びat2レセプターが関係する疾病の治療のためのイミダゾール誘導体の使用、いくつかのこれらの化合物、それらの製造、それらの薬剤としての用途並びにそれらを含有する製薬組成物 | |
JP3192171B2 (ja) | イミダゾールの新規な硫黄誘導体、その製造方法、得られる新規な中間体、薬物としてのその使用、及びそれを含有する医薬組成物 | |
RU2738844C2 (ru) | Содержащее заместитель, представляющий собой бутан, в гетероциклическом кольце производное пиридона для лечения фиброза и воспалительных заболеваний | |
JPH09509925A (ja) | インドールの新規な四置換誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての用途及びそれらを含有する製薬組成物 | |
JP3723585B2 (ja) | イミダゾールの含硫黄誘導体の新製造法及び得られる新中間体 | |
US5391732A (en) | Process for the preparation of biphenyl-imidazole derivatives | |
JPH11513704A (ja) | 酸性ピラゾールの新誘導体、それらの製造方法、それらの薬剤としての用途、それらの新規な用途並びにそれらを含有する製薬組成物 | |
JP4044134B2 (ja) | イミダゾールの誘導体の新規な用途、イミダゾールの新規な誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての用途及びそれらを含有する製薬組成物 | |
JPH10503512A (ja) | イミダゾールの新規な誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての用途及びそれらを含有する製薬組成物 | |
Corbier et al. | Method of preventing abnormal stimulation of AT 1 and AT 2 receptors | |
FR2675503A1 (fr) | Nouveaux derives soufres de l'imidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. | |
FR2664271A1 (fr) | Nouveaux derives soufres de l'imidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20041027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060928 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061019 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061031 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061110 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |